News

The objective is to optimize Fc receptor mediated antibody function. The work will be conducted in the Laboratory of Molecular Genetics and Immunology at The Rockefeller University, which

As part of the deal, HCI awarded LSKB global rights in all therapeutic indications of HCI-1401. Developed by HCI’s Center for investigational therapeutics, HCI-1401 was selectively designed to

To be conducted within the UCSF Helen Diller Family Comprehensive Cancer Center, the Phase II trial will investigate PEGPH20 in combination with gemcitabine and nab-paclitaxel (ABRAXANE) in patients

TD-8954 is being evaluated for potential use in the treatment of gastrointestinal motility disorders, including enteral feeding intolerance (EFI). Currently, TD-8954 is in Phase II clinical development having

Breo Ellipta is a fixed-dose combination (FDC) of the inhaled corticosteroid (ICS) fluticasone furoate and the long-acting beta2-agonist (LABA) vilanterol. In Canada two strengths 100/25mcg and 200/25mcg of

Additionally, the European Medicines Agency (EMA) has granted orphan designation for the same product to treat perinatal asphyxia, an alternate term that describes the same condition as NHIE,

The deal will see AstraZeneca acquire exclusive global rights from Heptares to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and

The CMA has issued a statement of objections to these two firms alleging that they have breached the UK and EU competition law. The drug, which is indicated

IPF affects in the region of 100,000 people in the US. Current products are expected to produce global revenues in excess of $1.1 billion by 2017. The LOXL2